These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


490 related items for PubMed ID: 15583642

  • 1. FDA and EMEA pool scientific advice.
    Katsnelson A.
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Muddied messages about FDA.
    Miller HI.
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Trials and error.
    Jacobs T.
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract] [Full Text] [Related]

  • 8. The special treatment.
    Osborne R.
    Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. BIO and biogenerics.
    Feldbaum CB.
    Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
    [No Abstract] [Full Text] [Related]

  • 11. What ails the FDA?
    Jenny-Avital ER.
    N Engl J Med; 2005 Jun 16; 352(24):2554-5. PubMed ID: 15962407
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. 8 keys to compliance for Medical Science Liaisons.
    Werling K, Heinze G.
    Health Care Law Mon; 2007 Apr 16; ():3-6. PubMed ID: 17476734
    [No Abstract] [Full Text] [Related]

  • 14. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN, Horvath CJ.
    Toxicol Pathol; 2009 Apr 16; 37(3):363-71. PubMed ID: 19246571
    [No Abstract] [Full Text] [Related]

  • 15. EMEA approves OGS drug rejected by FDA.
    Mitchell P.
    Nat Biotechnol; 2002 Sep 16; 20(9):858-9. PubMed ID: 12205490
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Who would approve new drugs if there were no FDA?
    Gatty B.
    Hosp Formul; 1995 Jan 16; 30(1):58, 57. PubMed ID: 10139726
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R.
    J Natl Cancer Inst; 2005 May 18; 97(10):708-9. PubMed ID: 15900036
    [No Abstract] [Full Text] [Related]

  • 20. The big gap at the FDA.
    Stipp D.
    Fortune; 2002 Jul 22; 146(2):113-4, 116. PubMed ID: 12141178
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 25.